Rhythm Biosciences (FRA:0RY) Current Ratio: 2.31 (As of Dec. 2025) — 60% Below Median


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.06
! 5 Warning Signs
View Full Analysis

What is Rhythm Biosciences Current Ratio?

Rhythm Biosciences FRA:0RY +5.50% 31 Current Ratio is 2.31 as of Dec. 2025, which is 60% below its 10-year median of 5.74. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Rhythm Biosciences ranks better than 54.21% on this metric.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rhythm Biosciences's current ratio for the quarter that ended in Dec. 2025 was 2.31.

Rhythm Biosciences has a current ratio of 2.31. It generally indicates good short-term financial strength.

The historical rank and industry rank for Rhythm Biosciences's Current Ratio or its related term are showing as below:

FRA:0RY' s Current Ratio Range Over the Past 10 Years
Min: 0.84   Med: 5.74   Max: 74.24
Current: 2.31

During the past 8 years, Rhythm Biosciences's highest Current Ratio was 74.24. The lowest was 0.84. And the median was 5.74.

FRA:0RY's Current Ratio is ranked better than
54.21% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99 vs FRA:0RY: 2.31

Rhythm Biosciences  (FRA:0RY) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Rhythm Biosciences Current Ratio Related Terms


Rhythm Biosciences Current Ratio Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Current Ratio Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Ratio
Get a 7-Day Free Trial 1.86 8.33 4.03 1.58 0.84

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 1.58 4.88 0.84 2.31

FRA:0RY vs TMO, DHR, IDXX: Current Ratio Comparison

For the Diagnostics & Research subindustry, Rhythm Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences Current Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Current Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Current Ratio falls into.


FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Current Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Rhythm Biosciences's Current Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Current Ratio (A: Jun. 2025 )=Total Current Assets (A: Jun. 2025 )/Total Current Liabilities (A: Jun. 2025 )
=1.023/1.219
=0.84

Rhythm Biosciences's Current Ratio for the quarter that ended in Dec. 2025 is calculated as

Current Ratio (Q: Dec. 2025 )=Total Current Assets (Q: Dec. 2025 )/Total Current Liabilities (Q: Dec. 2025 )
=1.235/0.535
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 2.31 mean?
Rhythm Biosciences (FRA:0RY) has a Current Ratio of 2.31 as of Dec. 2025. This is 60% below median its historical median of 5.74. Over the past decade, Rhythm Biosciences' Current Ratio has ranged from 0.84 to 74.24. According to the industry distribution chart, Rhythm Biosciences ranks #98 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 45.8%.
Is Rhythm Biosciences' Current Ratio too high?
Rhythm Biosciences' current Current Ratio of 2.31 is 60% below median its 10-year median of 5.74. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 74.24. The Medical Diagnostics & Research industry median Current Ratio is 1.99. Rhythm Biosciences' value of 2.31 is 16.1% above this industry median. Based on the distribution chart, Rhythm Biosciences ranks #98 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #98 out of 214 companies for Current Ratio. This puts Rhythm Biosciences in the upper half of its industry. The industry median Current Ratio is 1.99. Rhythm Biosciences' value of 2.31 is 16.1% above this benchmark. Historically, Rhythm Biosciences' own Current Ratio has ranged from 0.84 to 74.24 over the past decade. While the company's 10-year median is 5.74 vs. the industry median of 1.99, Rhythm Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.99, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current Current Ratio of 2.31 is 16.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current Current Ratio is 2.31, which is 60% below median its own 10-year median of 5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Current Ratio of 2.31. The current Current Ratio is 2.31, which is 60% below median its 10-year median of 5.74 and 16.1% above the Medical Diagnostics & Research industry median of 1.99. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Current Ratio is 2.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price